Øystein Rekdal

Algemeen Directeur bij LYTIX BIOPHARMA

Vermogen: 70 776 $ op 30-04-2024

Health Technology

Consumer Services

Actieve functies van Øystein Rekdal

Bedrijven	Functie	Begin	Einde
LYTIX BIOPHARMA	Algemeen Directeur	11-09-2019	-
	Oprichter	01-01-2003	-
	Directeur/Bestuurslid	26-04-2010	21-04-2011
	Hoofd Techniek/Wetenschap/O&O	-	11-09-2019
	Corporate Officer/Principal	01-01-2003	-
University of Tromso	Corporate Officer/Principal	-	-

Bedrijven	Functie	Begin	Einde
Prophylix AS Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.	Directeur/Bestuurslid	15-04-2010	-

University of Tromso

Doctorate Degree

Internationaal

Noorwegen

Operationeel

Director/Board Member	2
Corporate Officer/Principal	2
Chief Executive Officer	1

Sectoraal

Health Technology	3
Consumer Services	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
LYTIX BIOPHARMA	Health Technology

Bedrijven in privébezit	1
Prophylix AS Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.	Health Technology

Bedrijven in privébezit

Health Technology